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Frriburg, Lemony; Atlanta, Georgia; Amherst, Massachusetts 
Of&chs. We soogbt to exaodoe wbetber long-term nitroglyc- 
erin treatment causes toleraoeo in large caraeary arlwies and 
whether the loss of vascular elfects parallels neurobonnooal 
aQ&neots. 
Baekgrwnd. NitroglycwIn therapy is associated with increased 
plasma reoio acttvRy sod aldosterooe levels aod a decrease IO 
beomtoctit. It is assumed that titruglycerh tolenwe results in 
part fronn these oeurohormonal adjustments and intravascular 
volume expansion. 
hid. Tbrtt gray wtrt studied: group I (0 = lo), oa prior 
nUruglyctrio therapy sod gruup II (II = 10) aod groop III (II = 
II), 24. aod 72-b loog-term q itrodlyeeria iofusioo (0.5 &kg budy 
weIgbt per mini, respecthely. Cnruoary artery dimeosioos were 
assessed osiog quantRattve aoglograpby. Plasma reatn activity, 
plasma aldosteraoe and vasopressio levels aad beomtuerit were 
mooitored before aod during aitruglycerio iofosioos. 
lfesuh 10 gruup I, iorreashg iotraveoour c4meeotratioos of 
nitroglycerin caosed a dose-dependeot increase of tbe q idporRoo 
of tbe left anterior desceoding mroomy artery (bwlhe dhaeter 
2.13 zt 0.07 mm [mean A SEMI, ouuhally by 22 f 2%) and left 
chumRex corooary tiery (baseliae diameter 2.08 + 0.67 mm, 
maximally by 22 f 3%). Ao iotraeomnary q itn&certo klus 
(0.2 otg) caused no fiwtber significant increase in diameter, 
iodiitiag q nximal dilatioo. lo group II (II = IQ), tbe baseline 
The efficacy of nitroglycerin in the treatment of ischemic heart 
disease is dependent on its unique spectrum of in vivo activity: 
Nitroglycerin preferentially dilates large arteries, capacitance 
vessels and collateral channels, with little measurable effect on 
systemic and coronary vascular resistance (I). However, during 
long-term exposure the anti-ischemic cfbcacy of nitroglyrerin is 
large carooary artery diameter uoder ongolog ohglycerIn was 
sigailkootly larger than that in lpmrp I (IeR anterior d-odiog 
artty 2.61 f 0.08 mm, left chumRex arteg 2.57 2 0.08 mm). 
Additional intravenous aod Iotracam oitroglycerh &al- 
legs did not cause fhtber dilation, iodtcatIog maxtomlly d&&d 
vessels. At tbe some time, plasma renio activity, plasma aIdor& 
rone and vasopressto levels were GgoIIcaotly increased, aod 
beamtacrit sIgo&aotly dewea&.IoginopIIIpatteots,tbe 
bastliit diameter of tbe leR anterior descend& artery aod tbe 
left &coo&x srtery did not dIIr hwa tbat in patteots dtbuot 
nitrogiyttrio prttrtatmtot, idiating a wnplete lass of oitra- 
glyttria eonmary vaaodihtive tfleets. Tbtst paths sbowtd 00 
sigo&aot increase in circolating neorohoromoal levels but a 
sigoIRcaot decrease io hematucrtt. 
conrludonr. Within 24 b of continuous oitruglycerio treat- 
ment, tbt corooary arterks were amximally dilated despite oeu- 
robormonal adjostowots aad sIgos of intravascular volmne ex- 
pansion. WItbin 3 days of ottrogfycerh Iotiwtoa, toleraoce 
developed Io tbt absence of oeoraborauma I acttvatioa. Tbe dIs- 
wciation of oeorabormooal adjustments aod tolerance in large 
tnrnaaiy arteries indkatts that after loog-term oitraglycertn 
treatment, true vascular tolernoce, perbaps ttom ao iotrac&dar 
t&-ante sttp, may bavt developed. 
(J Am call cknfiol1996;3?:297-303) 
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rapidly blunted by the development of tolerance (2- 4). Several 
mechanisms have been suggested to account for this phenom- 
enon. Mechanisms extraneous (so-called pseudotolerance) to 
the vessel wall include neurogenic countemegulatory mecha- 
nisms (2,3) and intravascular volume expansion (5). Neuro- 
genie counterregulatoiy mechanisms may offset the direct 
vascular effects of nitroglycerin and, together with sodium and 
water retention, may counterbalance the ventilator cLcts of 
this drug. In experimental animals, tolerance has also been 
shown to be related to an inability of the vascular smooth 
muscle to cunvert nitroglycerin to nitric oxide (so-called true 
vascular tolerance [6-81). There has been substantial debate 
on the extent to which these two mechanisms contribute to the 
loss of antianginal efficacy during long-tern nitroglycerin 
therapy, and the notion thaa neurvhumoral mechanisms are a 
pwlomioaot cause has achiired sukaotial popularity (23). 
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This issue is confounded by the multiple effects of nitro- 
glycerin and the various variables that may be examined. 
Studies that examine only peripheral consequences of nitro- 
glycerin therapy may not detect changes in corona0 r3scular 
responses to nitroglycerin. Therefore, the aim of rhe present 
study was 1) to determine whether the nitroglycerin-induced 
dilation of large epicardial arteries is subject to tolerance 
under long-term nitroglycerin treatment; and 2) to evaluate the 
effects df continuous nitroglycerin treatment on neurohor- 
monal variables to establish whether the reflex activation of 
neurohormonal vasoconstrictor forces is able to attenuate the 
nitroglycerin coronary vasodilator effects. 
Methods 
Patierats. The subjects were patients Ir,lciergoing routine 
diagnostic cardiac cathetenzatron for evaluation of chest pain. 
Patienib with unstable angina. recent myocardia! infarction 
(<l month), significant vaivular heart disease or clinical 
evidence of heart failure were excluded. The study protocol 
was ;pproved by the ethics committee of the University of 
Freit;urg. Written informed ionsent was obtained from all 
pa:ients. We evaluated three groups of patients with suspected 
coronary artTry disease. Group I included 10 patients without 
nitroglycerin pretreatment (9 men, 1 woman; mean t SEM 
age 53 ?1 4 years). Diagnostic catheterization revealed signif- 
icant coronary artery disease (defined as >50% stenosis in one 
or more vessels) in eight patients (four with two-vessel disease, 
four with one-vessel disease). Two patients had normal coro- 
nary arteries. Group i i included 10 patients (8 men, 2 women; 
mean age 56 2 4 years) pretreated with nitroglycerin for 24 h 
(0.5 &kg body weight per min). Two patients in group II had 
normal coronary arteries, and eight patients had significant 
coronary artery disease (one with three-vessel disease, three 
with two-vessel disease, four with one-vessel disease). Group 
HI included iight patients (seven men, 1 woman; mean age 
52 rt 3 years) who had received nitroglycerin 0.5 @kg per min 
for 72 h (two patients with two-vessel disease; five with one 
vessel disease). One patient had normal coronary arteries, and 
seven had significant coronary artery disease. 
Study design. Antianginal medications (beta-adrenergic 
blocking agents, calcium antagonists and long-acting nitrates) 
were discontinued at least 24 h before the study. All studies 
were done in the morning between 8 and 11 AM. The experi- 
mental protocol was performed after the left heart catheter- 
ization with the subjects in the fasting state and premeditation 
with 10 mg of oral diazepam. 
After baseline measurements, nitroglycerin was given to 
patients without nitroglycerin pretreatment in the following 
sequence: 1) 0.05 &kg per min intravenously for 7 min; 2) 
0.15 p@kg per min intravenously for 7 min; 3) 0.5 a per 
rnin intravenously for 7 min; 4) 2@0 a into the left main stem 
to assess the maximal vasodiiator capacity of the left epicardial 
coronary arteries. 
Tbughout the study, aortic pressure and heart rate were 
continuously monitored. Nitmglycerin was infused intrave- 
nously with an infusion pump (Braun Melsungen) set at a flow 
rate of 2 ml/min. At the end of each infusion (and also 5 min 
after the intracoronary nitroglycerin bolus), biplane coronary 
angiograms were taken. After a dose-response relation for 
intravenous nitroglycerin and large coronary artery dilation 
had bekn established in patients without nitroglycerin pretreat- 
ment, patients were randomly assigned either to the 24-h 
(group II) or 72-h nitroglycerin treatment group (group Ill), 
where the identical protocol was performed. For long-term 
infusion, nitroglycerin at 0.5 &kg per min was chosen, 
because this particular concentra:ion caused a maximal dila- 
tion of the left anterior descending and left circumflex coro- 
nary arteries (Fig. 1). Throughout the protocol for groups If 
2nd III, long-term nitroglycerin infusion was continued. 
Quantitztive coronary mgiography. Coronary angiogra- 
phy was done with a simultaneous biplane multidirectional 
isocentric radiographic system (Siemens Bicor). End-diastolic 
tine frames of biplane cineangiograms were videodigitized and 
stored in a Mipron I image analysis system (Kontron Electron- 
ics) in a 512 x 512 matrix with an eight-bit gray scale as 
described previously (10). Quantitative coronary angiography 
of midsegments of the left circumflex and left anterior de- 
scending coronary arteries was done by automatic contour 
detection, which was validated by a method that incorporates a 
geometric edge differentiation technique. If proximal left 
circumflex artery or left anterior descending artery stenosis was 
present, segments distal to the stenosis were analyzed. Calcu- 
lation of the exact radiologic magnification factor of the 
measured segment was used to scale the data from pixels to 
millimeters as previously described (11). The accuracy and 
precision of this technique, as well as the reproducibility of 
serial measurements under routine clinical conditions, have 
been established (10). The evaluation of the angiograms was 
done by a technician who was unaware of the patients’ 
pretreatment conditions. Plasma samples for analysis of aldo- 
sterone, vasopressin and plasma renin activity were obtained in 
a supine zosition after a 30-min rest period and 1 h before 
diagnostic catheterization. In patients treated with nitroglyc- 
erin for 24 or 72 h, blood samples were drawn at a similar time 
of day. Plasma renin activity and plasma aldosterone and 
vasopressin levels were determined as described recently (9). 
We also performed additional studies to exclude a con- 
founding contribution of coronary artery diameter variability 
to our data. To address that issue, we also analyzed midseg- 
ments of the left anterior descending coronary artery by 
quantitative coronary angiography in 20 patients of similar age 
(55 t 2 years) and with a similar degree of coronary artery 
disease (8 with two-vessel disease, 10 with one-vessel disease, 2 
without significant coronary artery stenosis). 
Statistical analysis. All data are expressed as mean 
value ?z SEM. For within-group comparisons, a one-way 
analysis of variance for multiple comparisons was applied, 
foliowed by a I test with Bonferroni’scorrection for the number 
of comparisons. For direct comparison of the overall dose- 
response relation with respect to large coronary artery dii- 
eter and systemic hemdynamic variables, an ana&& of co- 
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Figure 1. Effects of increasing intravenous 
(iv.) and intracoronary nitroglycerin (NTG) 
on large coronary artery diameters in pa- 
tients without (group I) and with 24 h 
(group II) and 72 h nitroglycerin pretreat- 
ment (group III). Under ongoing nitroglyc- 
erin infusions, patients pretreated with ni- 
troglycerin for 24 h did not respond with a 
further increase In diameter, indicating a 
maximally dilated coronary artery. In con- 
trast, patients orctreated with nitroglycerin 
for 3 days respoud~? with a diameter in- 
crease that was not statistically different 
from those of group I, which is strongly 
suggestive of tolerance development in 
large epicardial arteries. Increasing concen- 
trations of nitroglycerin were given intrave- 
nously for 7 min each. C = control; B = 
0.2-mg intracorouary nitroglycerin bulu: ; 
LAD = left anterior descending coronary 
artery; LCx = left circumflex coronary ar- 
tery. Data shown are mean value + SEM 
(apea sqaares) and individual data. *Sigrlif- 
icantly different from baseline values (after 
Bonferonni correction for the numbers of 
comparisons [n = 41). 
variance was performed. The variables were treatment and 
baseline coronary artery diameter, baseline mean arterial 
pressure or baseline heart rate, respectively. Baseline diame- 
ters of all three groups were compared using one-way analysis 
of variance. To analyze the effects of nitroglycerin treatment 
on neurohomtonal variables, comparisons were made by a 
paired I test; p < 0.05 was considered significant. 
Results 
EtRcts of nitroglycerin OII large epicardial artery diameter. 
In patients not pretreated with organic nitrates, an Wsvenous 
nitroglycerin infusion (0.05,0.15 and 0.5 @kg per min) caused 
a dose-dependent increase in the diameter of the midportion 
of the left anterior descending coronary artery (baseline 2.13 t 
0.07) by 7 + I %, 16 2 3% and 23 2 2% and the left circumflex 
coronary artery (baseline 2.08 t 0.07 mm) by 5 -C 2%, 12 + 3% 
and 22 2 3% (Fig. 1). Intraeoroaary bolus injection of 
nitroglycerin 0.2 mg did not produce additional significant 
dilation (left anterior descending artery 24 k 2% vs. baseline; 
left circumflex artery 23 2 3% vs. baseline), indicating that 
intravenous nitroglycerin infusion in a concentration of 
0.5 pg/kg per min intravenously was sufficient to cause maximal 
dilation of large epicardial eonduetanee vessels in normoten- 
sive patients. 
In patients pretreated with nitroglycerin for 24 h (grouB II), 
the average baseline diameter for the left anterior descending 
artery (2.612 0.08 mm) and the left eiretmdkx artery (2.57 t 
0.08 mm) were significantly (p = 0.01 and 0.012, respectively) 
higher than the average baseline values in group 1. Additional 
intravenous and intraeomnaty nitmglyeerin challcngcs did not 
kad to further sign&ant changes of the diameter of the 
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crqohg WTG 0.5 p@qIndn ix 
midportion of the left anterior descending artery (maximally 
I -C I%, ns) or the left circumflex artery (maximally 2 t 1%). 
In contrast. the baseline diameter of the left anterior 
descending artery (2.10 t 0.08 mm) and the left circumflex 
Brtery (2.16 t 0.04 mm) of patients treated with nitroglycerin 
for 72 h (group III) did not differ significantly (p = 0.973 and 
0.835, respectively) from baseline values of patients without 
nitroglycerin treatment (group I) and were significantly smaller 
than those m patients treated with nitroglycerin for 24 h (p = 
0.011 and 0.010, respectively). Additional short-term chal- 
lenges with intravenous nitroglycerin at 0.05, 0.15 and 
0.5 @kg per -in and intracoronaty nitroglycerin at 0.2 mg 
under tngoing nitroglyeerm (0.5 @kg per min) caused a 
dose-dependent increase in coronary artery diameter similar to 
that in group 1 (left anterior descending artery by 4 + 1%. 8 t 
l%, 14 t 2% and 18 z 2%; left circumflex artery by 5 t 1%, 
9 t 2%,14 2 2% and 17 + 2%). 
The overall dose-response relation for large coronary ar- 
tery dilation for groups I and III was not signikantly different 
(p = 0.96). In contrast, there were significant differences 
between groups I and II (p = 0.020) and between groups II and 
1110, = 0.021). The calculated ED, (nitroglycerin eoneeotrs- 
tion that causes half-maximal dilation of the left anterior 
descending artery) for group III was 0.66 + 0.02 &kg per min 
and therefore signifkantly (p = 0.01) higher compared with 
that for patients without nitroglycerin pretreatment (0.11 t 
0.02 &cg per min). 
In separate studii we analyzed the diameter of the mid- 
segment of the left anterior descending coronary artery in 20 
patients with eoronaty artery d&ease. The diameter of the left 
anterior descending coronary artery averaged 2.18 2 0.05 mm 
and was therefore not signiintly diierent from diameters in 
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Fiire 2. Effects of increasing intravenous (iv.) and intracoronary 
(ix.) nitroglycerin (NTG) concentrationson heart rate (HR) and mean 
arterial pressure (MAP) in patients without (group I [solid circksl) 
and with’ nitmgly&in p~etr&tment for 24 h (&oup II [triangles]) or 
72 h (group III [open circles]). Changes in systemic hemodynamic 
variables in response Lo nitroglycerin were similar in groups I and II. 
However, the overall dose-response relation was significantly blunted 
in patients treated with nitroglycerin for 72 h. Bolus = 0.2~mg 
intracoronary nitroglycerin bolus: bpm = beats per minute. Data are 
expressed as mean value 2 SEM. *Significantly different from control 
(C) values (after correction for the number of comparisons [n = 41). 
tp < 0.05 versus overall hemodynamic response of groups I and II. 
patients from groups I and III; however, it was significantly 
different from diameters in patients included in group 11. 
Intracoronary bolus injection of nitroglycerin in a concentra- 
tion of 0.2 mg in 11 patients increased the diameter of the 
mi&egment of the left coronary artery diameter from 2.15 + 
OS& to 2.68 ? 0.8 mm; the latter was not different from 
diameters in patients receiving ongoing NTG infirsion for 24 h 
(proup II). 
Systemk hemodyna& variabtos. In patients without ni- 
t.rogIycerin pretreatment (group I) (Fig. 2), increasing concen- 
trations of nitroglycerin caused a dose-dependent increase in 
heart rate (baseline 70 i 4 beats/min) by maximally + 15 ? 4% 
and drop in mean arterial pressure (baseline 102 -C 5 mm Hg) 
by maximaNy - I2 2 3%. In patients treated with nitroglycerin 
for 24 h (group II), short-term nitroglycerin challenges re- 
sulted in similar changes in systemic hemodynamic variables 
(heart rate: group I vs. group II, p = 0.95 [NSJ; mean arterial 
pressure: group I vs. group II, p = ,0.43 INS]). In patients 
treated with nitroglycerin for 72 II the overall response in heart 
rate @ = 0.014) and mean a;:rial pressure (p = 0.034) was 
significan$ attenuated compared with that in group I (Fig. 2). 
Effects of nitrogtyeerin iafa&m on wwohormonal sari- 
&es mid p&ma benmtoc& Intravenous nitroglycerin infu- 
sion for 24 h signiticantty increased plasma renin activity (p = 
0.03) and plasma ahlosterone (p = 0.02) and vasopressin (p = 
0.007) levels (group II), (Fig. 3). Neurohormonal activation 
was accompanied by a signilicant drop in plasma hematocrit 
(p = O.OI), indicating iatravasudar volume expansion. In 
group III, neurohormonaI activity after a 72-h nitroglycerin 
iufusion period dii not differ significantIy from control values, 
whereby hmatocrit was sisnifimtiy (p = 0.001) reduced. 
Group IIt 
HCT 
v-1 ba 
4Q 
c 24hNTQ C 72hNTQ 
Figure J. Effects of 24-h and 72-h nitroglycerin infusion, respectively, 
on plasma renin activity (PRA), plasma aldosterone levels (ALDO), 
plasma vasopressin levels (ADH) and hematocrit (HCi’). Datg are 
p*es:nted as mean value _+ SEM. *p < 0.05 versus mntrol values (C). 
Discussion 
The present study provides important information regard- 
ing the time course and mechanisms of nitrate tolerance dut ;ng 
long-term intravenous nitroglycerin infusion. To our knowl- 
edge, this is the first demonstration that activation of circulat- 
ing neurohormonal vasoconstrictor forces during the first 24-h 
nitroglycerin treatment period does not attenuate its corrtnary 
vasodilator effects. In contrast, after 3 days of nitroglycerin 
treatment, tolerance in both large epicardial arteries and the 
systemic vasculature develops without further -,&A tif activa- 
tion of circulating neurohormones. Considered togetl,-r. :he 
dissociation between neurohonuonal adjustments and vascular 
tolerance in coronary arteries suggests that during the early 
phase of nitroglycerin infusion, neurohormonal activation does 
not attenuate large coronary artery vasodilation to nitroglyc- 
erin. However, after 3 days of continuous treatment, tolerance 
in large coronary arteries developed, as evidenced by a return 
to baseline size and a return of responsiveness to large doses of 
additional nitroglycerin. Because this occurred in the absence 
of further neurohumorai adjustments, it is likely that it was 
largely a result of intrinsic abnormalities of the t&rant 
vasculature. 
A major aspect of the present study is the means used to 
define large coronary artery toferance to nitrogIycerin. As an 
index of nitrogIyeerin tolerance, we used the capacity of 
i#usions of large concentrations of nitmg&erin superim- 
po6ed on ongoing nitrogIy&n treatment to cam further 
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vasodilation. We reasoned tha! additional higher concentra- 
tions of nitroglycerin would be unable to vasodilate vessels 
maximally dilated by nitroglycerin, whereas vessels in which 
the’ nitroglycerin effect was lost because of tolerance would be 
dilated by larger amounts of the drug. This assumption is based 
on extensive data from previous studies in animals and humans 
showing that high concentrations of nitroglycerin can consis- 
tently dilate coronary arteries tolerant to lower doses of the 
drug (12-15). 
timltatinn of the study. One potential criticism of this 
work is that the baseline diameters of the vessels studied varied 
among the three groups of patients. This seems unlikely for 
two reasons: 1) A widely accepted approach to estimating 
passive diameter (in the absence of tone) is to obtain measure- 
ments after the vessel is maximally dilated by nitroglycerin. 
This, in fact, was the measurement obtained after bolus 
injections of nitroglycerin in all three groups. Examination of 
Figure 1 shows that after a bolus injection of nitroglycerin, the 
coronary diameters were remarkably similar among the three 
groups of patients. This finding indicates that the decrease in 
baseline diameter observed in group III did not result from an 
intrinsic difference in the size of the vessel but from an inerease 
in tone (likely related to loss of the effect of the nitroglycerin 
infusion effect). 2) In an additional 20 patients with similar risk 
profile, age and degree of coronary artery disease, we studied 
the baseline diameter of the midsegment of the left anterior 
descending artery. The average diameter did not dither signif- 
icantly from the average diameter of patients without nitro- 
glycerin pretreatment or of patients treated with nitroglycerin 
for 3 days. Furthermore, intracoronary bolus injections in 11 
patients resulted in an average coronary artery diameter that 
was not different from that from patients under ongoing 
nitroglycerin infusion for 24 h. On the basis of these results, we 
believe that the larger diameters in the 24-h group compared 
with either the control group or the 72-h nitroglycerin infur;in 
group resulted from a continued effect of nitroglyc. I in that 1s 
subsequently lost at 72 h. 
Tolerance in large coronary arteries: ps~udotolemnee ver- 
sus true vascular tolerance. The anti-acch:mic etTects of or- 
ganic nitrates are rapidly blunted during continuous treatment 
with nitroglycerin infusion (2,4,16), isosorbide dinitrate (17) or 
nitroglycerin patches (18). Zimrin et al. (4) reported a marked 
attenuation of exercise tolerance in patients with stable coro- 
nary artery disease treated with nitroglycerin for 24 h. They 
speculated that activation of neurogenic vasoconstrictor forces 
might override the nitroglycerin vascular effects. The hypoth- 
esis that pseudotolerance mechanisms play a substantial role in 
nitrate tolerance is also supported by clinical data demonstrat- 
ing that a nitrate-free interval prevents neurohormonal adjust- 
ments and parallel tolerance development (2). Furthermore, a 
causal role of nemohormones in nitroglycerin tolerance is 
indirectly supported by observations that concomitant admin- 
istration of inhibitors of angiotensin-amverting enzyme are in 
some but not ail instances able to reverse or prevent tolerance 
(19-22). To address the eventual role of nemohormonal 
adjustments in nitrate tolerance of large epicardial arteries, we 
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examined responses of these vessels io increasing doses of 
nitroglycerin and measured plasma aidosterone, plasma vaso- 
pressin and plasma renin activity before and during 24 to 72 h 
nitroglycerin infusion. As a marker of intravascular volume 
expansion, hcmatocrit was determined. The nitroglycerin con- 
centration used for long-term infusion (0.5 @kg per min) was 
sufficient to cause maximal dilation of the left coronary artery, 
and the degree of diameter increase of :he left anterior 
descending artery and the left circumflex artery (maximally 
+24%) is comparable to that reported after intracoronaty 
nitroglycerin administration (23). 
In the present studies we were able to demonstrate that 
within 24 h of continuous nitroglycerin treatment, the large 
coronary conductance vessels are still maximally dilated This 
conclusion was based on observations tha! during conrinuc~ti 
nitroglycerin infusion, the baseline diameters of the left core- 
nary artery of group 11 were significantly higher than baselinl: 
~.alues of control patients and did not diEer from the maximally 
dilated diameters in group 1. The maxima! dilation observed 
after 24 h of nitroglycerin infusion indicated a continued 
nitroglycerin effect explaining the lack of effect of additional 
intravenous and intracoronary nitroglycerin challenges on left 
anterior descending and left circumflex artery (Fig. 1). 
At the same time. we observed an increase in plasma renin 
activity, plasma aldosterone and vasopressin levels and a 
decrease in hematocrit. These changes represent neurohor- 
mortal adjustments and, as previously reported, are secondary 
to the hypotensive action of nitroglycerin (3,4) and other 
vasodilatom (2425). The lack of tolerance in large epicardial 
arteries provides direct evidence that, similar to experimental 
findings (1.5,26,27), activation of circulating neurohormonal 
vasoconstrictor forces does not impair nitroglycerin induced 
dilation of large coronary arteries. 
After 72 h of continuous nitroglycerin treatment, the base- 
line diameter of the left circumflex artery or the left anterior 
descending artery under ongoing nitroglycerin infusi, m did not 
differ significantiy from the baseline diameters of patients 
without nitroglycerin treatment, indicating an &most complete 
loss of coronary vasodilation. 
This time course of nitroglycerin tolerance development in 
large coronary arteries is in keeping with recent experimental 
(13,15,28) and clinical data (12). During long-term nitroglyc- 
erin or isosorbide dir&ate infusion, the coronary arteries were 
maximally dilated 24 h after initiation of a Sday nitroglycerin 
infusion period, and tolerance was well established by the third 
to fifth day of treatment. 
Another important finding of the present study is that 
vascular tolerance after 72-h nitroglycerin infusion is not 
associated with further evidence of neurohumoral activation 
(Fig. 3). At this time, plasma aldosterone and vasopressin 
levels and plasma renin activity did not differ from values 
before nitroglycerin treatment. A similar transient pattern of 
neurohormonal adjustments during long-term nitmglycertn 
treatment was recently reported (3). In this previous study, 
treatment of healthy volunteers with nitmglycerin patches led 
to an increase in plasma renin activity and plasma aldosterone 
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and vasopressin levels (comparable to group II) during the first 
day of treatment. In patients treated with nitroglycerin for 3 
days, however, all three variables had returned to baseline 
(comparable to group III). 
The demonstration of tolerance in large epicardial arteries 
in the absence of further increased neurohormonal activity 
makes it very unlikely that pseudotolerance mechanisms are 
responsible for that phenomenon. Normalization of circulating 
angiotensin II, aldosterone and vasopressin levels within 72 h 
of continuous nitroglycerin treatment, however, does not com- 
pletely exciude that neurohonnonal factors (e.g., plasma cat- 
echolamines) may limit nitroglycerin’s coronary vasodilator 
effect at this time point. Plasma levels of these substances do 
not reflect changes in hormone turnover rates, neurohormonal 
clearance rates or the density of the respective receptors 
involved. Furthermore, a return of neurohormonal levels to- 
ward normal values may reflect a new homeostatic balance 
rather than normal neurohormonal activity. Notwithstanding 
these arguments, we believe that the attenuated activity of 
circulating neurohormones after a 3-day nitroglycerin treat- 
ment indicates that in addition to continued volume expansion, 
true vascular tolerance may have developed. This in turn may 
,diminish barorellex stimulation and subsequently neurohor- 
monal activation. 
nitroglycerin effects on systemic hemodynamic variables was 
observed after a 3-day infusion period. However, tolerance to 
the blood pressure-lowering effects of organic nitrates has been 
reported to occur within 24 h of continuous treatment (29). 
Therefore, Gur data may indicate that tolerance to systemic 
hemodynamic effects, which is usually established within 24 h 
of continuous nitrate therapy, can be overcome by additional 
nitroglycerin challenges. After 3 days of continuous nitroglyc- 
erin treatment, additional short-term nitroglycerin challenges 
were able to cause a graded response of tolerant large coronary 
arteries but f&led to induce significant changes in heart rate 
and mean arterial pressure. This phenomenon has also been 
observed in chronically instrumented dogs (13,28) and may 
indicate that the nitroglycerin concentrations chosen were 
sufficient to overcome tolerance in large coronary arteries but 
may be too small to overcome tolerance in the systemic 
circulation. 
In contrast to the transient changes in neurohormonal 
variables, we observed a consistent drop in hematocrit in 
patients treated with nitroglycerin for 72 h. A decrease 
in hematocrit during long-term nitroglycerin treatment is in 
agreement with previous observations and very likely reflects 
intravascular volume expansion secondary to a transvasdular 
shift of fluid as a result of an alteration in Starling forces or a 
phenomenon related to an aldosterone-mediated salt and 
water retention (3,519). Recently, Parker and Parker (19) 
suggested thrit plasma expansion plays a more important role 
than neurohormonal responses in the loss of nitrate effects. 
During therapy with transdermal nitrates, they observed only 
modest and transient changes in neurohormonal variables, 
whereas, similar to our study, hematocrit decreased signifi- 
cantly and remained suppressed during long-term therapy (19). 
A considerable part of intravascular volume expansion, how- 
ever, occurs within the Iirst kour of nitroglycerin treatment (S), 
when nitroglycerin effects on large conductance vessels or 
central 6Iling pressures are in general maximal. Therefore, a 
significant decrease in hematocrit may bk used more as a 
marker for nitroglycerin treatment than as a marker for 
tolerance development. In addition, the persistent drop in 
hematocrit actually lends support to the conclusion that toler- 
ance to epicardial artery effects does not follow the same time 
line as tolerance in other vascular beds. 
W&at medaniims are responsible for attenuation of nitro- 
gBycertn action within the 24 and 72-b infusion periods? 
Numerous studies have documented an early loss (within 24 h) 
of the nitroglycerin effects during continuous treatment 
(2,4,16). It remains to be determined whether neurohormonal 
counterregulatory mechanisms or changes intrinsic to the 
tolerant vasculature itself play a major causal role in this 
phenomenon. Our data indicate that within 24 h of continuous 
nitroglycerin treatment, the vasodilator effects of nitroglycerin 
on large coronary arteries are preserved even in the presence 
of neurohotmonal adjustments and signs of intravascular vol- 
ume expansion. Vasopressin and angiotensin II are potent 
constrictors of small arterioles (30,31), a vessel region that has 
been demonstrated to be itself nitrate insensitive (32,33). 
Therefore, it is tempting to speculate that within 24 h of 
continuous nitroglycerin treatment, the sensitivity of large 
epicardial arteries to nitroglycerin has not changed, and 
pseudotolerance rather than true vascular tolerance mocha- 
nisms is responsible for the well-known rapid loss of the 
nitroglycerin vasodilator effects within this time frame. How- 
ever, within 3 days of continuous nitroglycerin infusion toler- 
ance in large epicardial arteries occurred even in the absence 
of further neurohormonal -ctivation. This observation indi- 
cates a desensitization of coronary conductance vessels to 
nitroglycerin, which might possibly be related to enhanced 
destruction of nitric oxide by vascular superoxide anion pro- 
duction (34) or may be secondary to an increase in sensitivity 
to vasoconstrictors (35) cr to oxidation of the enzyme respon- 
siDle for nitroglycerin biotransformation (36). 
We appreciate the a&tance of Ann B. Peterson in the preparabzm of the 
manuseripr. _I 
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